MARKET

YCBD

YCBD

cbdMD Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

2.580
-0.010
-0.39%
Closed 19:40 07/29 EDT
OPEN
2.600
PREV CLOSE
2.590
HIGH
2.680
LOW
2.520
VOLUME
124.92K
TURNOVER
--
52 WEEK HIGH
6.83
52 WEEK LOW
1.760
MARKET CAP
145.56M
P/E (TTM)
-3.5621
1D
5D
1M
3M
1Y
5Y
Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%
/PRNewswire/ -- Cannabidiol derived from hemp is anticipated to witness rapid growth owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health. Increasing consumer disposable income along with the legal...
PR Newswire - PRF · 1d ago
Sundial Growers, MedMen, World Acceptance Among Top Cannabis Stock Movers On July 26, 2021
GAINERS: Khiron Life Sciences (OTC: KHRNF) shares closed up 10.23% at $0.25
Benzinga · 3d ago
AusCann, Flower One, Item 9 Labs & MariMed Among Top Cannabis Stock Movers On July 23, 2021
GAINERS: Cann Gr (OTC: CNGGF) shares closed up 20.58% at $0.35
Benzinga · 6d ago
Bullish Sentiment Pumps Up Cannabis Stocks: Tilray, Sundial, Aurora & GrowGen Among Top Cannabis Movers For July 20, 2021
GAINERS: Empower Clinics (OTC: EPWCF) shares closed up 18.43% at $0.39
Benzinga · 07/20 21:58
BRIEF-cbdMD Enters Into Letter Of Intent To Buy DirectCBDOnline.com
reuters.com · 07/19 12:09
cbdMD Enters into Letter of Intent To Purchase DirectCBDOnline.com
cbdMD, Inc. (NYSE:YCBD, YCBDpA)), one of the leading, and most highly trusted and recognized CBD companies, announced today that it has entered into a letter of intent to purchase leading CBD online marketplace,
Benzinga · 07/19 12:02
cbdMD Enters Into Letter of Intent to Buy DirectCBDOnline.com From Twenty Two Capital
MT Newswires · 07/19 10:25
Australis, CV Sciences And MedMen Among Top Cannabis Stock Movers On July 9, 2021
GAINERS: Livewell Canada Inc (OTC: LMLLF) shares closed up 12.59% at $0.06
Benzinga · 07/09 22:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of YCBD. Analyze the recent business situations of cbdMD Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average YCBD stock price target is 5.42 with a high estimate of 8.00 and a low estimate of 3.250.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 2.71M
% Owned: 4.81%
Shares Outstanding: 56.42M
TypeInstitutionsShares
Increased
9
794.82K
New
25
1.06M
Decreased
1
42.37K
Sold Out
5
88.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.26%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Co-Chief Executive Officer/Director
Martin Sumichrast
Co-Chief Executive Officer/Director
Raymond Coffman
Chief Financial Officer
T. Ronan Kennedy
Senior Vice President
Francisco Mangual
Chief Marketing Officer
Ken Cohn
General Counsel
Lance Blundell
Other
John Wiesehan
Director/IR Contact Officer
John Weston
Independent Director
Peter Ghiloni
Independent Director
William Raines
Independent Director
Bakari Sellers
Independent Director
Scott Stephen
No Data
About YCBD
cbdMD Inc, formerly Level Brands, Inc., owns and operates consumer hemp-based cannabidiol (CBD) brand, cbdMD. The Company’s products categories include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD Vape oils and CBD pet products.

Webull offers kinds of cbdMD Inc stock information, including AMEX:YCBD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YCBD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading YCBD stock methods without spending real money on the virtual paper trading platform.